Price
Target price
€65.82
€65.82
-0.510%
-0.34
-0.510%
€76.30
07:53 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Halozyme
sharewise wants to provide you with the best news and tools for Halozyme, so we directly link to the best financial data sources.
Financials
News
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights